News
Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
1+ week, 5+ day ago (281+ words) Health Canada approves PrAJOVY" (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17years and weighing at least 45kg. PrAJOVY" increases availability across age groups as the first and…...
A drug made from marijuana reduced back pain in a large study
4+ mon, 2+ week ago (441+ words) The 800-patient study by a German drugmaker is the latest evidence of the therapeutic properties of cannabis, which remains illegal under U.S. federal law even as most states have made it available for medical or recreational use. Health officials in Canada…...
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
7+ mon, 3+ week ago (404+ words) Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI:…...
Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach
8+ mon, 3+ day ago (355+ words) Co-authored by leading pain specialists from institutions such as Johns Hopkins University and NYU School of Medicine, the review highlights that synthetic CBD administered through extended-release formulations could offer a well-tolerated, non-opioid analgesic alternative with the potential to significantly reduce…...
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
8+ mon, 4+ week ago (569+ words) Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant improvement in CMT-HI and statistically significant correlation between percent change in sorbitol and change in CMT-HI at 12 months…...
B.C. opioid rules were to reduce overdoses. But they cut cancer patients' pain meds
9+ mon, 2+ day ago (801+ words) Rule changes designed to reduce opioid overdose deaths in British Columbia in 2016 inadvertently harmed cancer and palliative-care patients by reducing their access to pain killers, a new study has found. The study published this week in the Canadian Medical Association…...
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting
10+ mon, 1+ week ago (1584+ words) TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two pivotal double-blind randomized Phase 3 studies…...
Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition
10+ mon, 2+ week ago (1364+ words) Tonix expands its all-in-one platform, partnering with the world's leading migraine diary app, enhancing disease education and prescription accessCHATHAM, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with a portfolio of marketed products and a pipeline…...
Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
11+ mon, 1+ week ago (228+ words) Pilavapadin achieved meaningful pain reduction versus placebo and was well-tolerated in the 10 mg dose, meeting the Company's objectives for the study Advancement of 10 mg dose into Phase 3 development in DPNP supported by both PROGRESS and RELIEF DPN-1 studies, which collectively…...
Brains Bioceutical's Natural CBD Isolate Achieves Landmark Safety Approval from UK Food Standards Agencies
11+ mon, 2+ week ago (266+ words) Brains Bioceutical Corp. (Brains Bio), a global leader in natural, GMP-compliant cannabinoid Active Pharmaceutical Ingredients (APIs), has achieved a major milestone'securing safety approval from the UK's Food Standards Agency (FSA) and Food Standards Scotland (FSS) for its natural CBD Isolate…...